Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of iparomlimab + tuvonralimab with anlotinib in recurrent or metastatic SMARCA4-deficient non-small cell lung cancer
ChiCTR2600131693Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600131693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131693.